Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis

Circulation Research

Volumn 120, Issue 4, 2017, Pages 713-735

  Förstermann, Ulrich ^a   Xia, Ning ^a   Li, Huige ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

atherosclerosis; nitric oxide; oxidative stress; reactive oxygen species; risk factors

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CATALASE; CELL ADHESION MOLECULE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; THIOREDOXIN; XANTHINE OXIDASE;

ATHEROSCLEROSIS; BIOACCUMULATION; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL ACTIVATION; DIABETES MELLITUS; ENDOTHELIUM CELL; FOAM CELL; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID OXIDATION; MACROPHAGE ACTIVATION; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; SMOKING; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SPECIES SPECIFICITY;

EID: 85013350343     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.309326     Document Type: Review

References (355)

1. Stocker R, Keaney JF Jr., Role of oxidative modifications in atherosclerosis. Physiol Rev 2004 84 1381 1478. doi: 10.1152/physrev.00047.2003
2. Förstermann U, Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008 5 338 349. doi: 10.1038/ncpcardio1211
3. Förstermann U, Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010 459 923 939. doi: 10.1007/s00424-010-0808-2
4. Li H, Horke S, Förstermann U, Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014 237 208 219. doi: 10.1016/j.atherosclerosis.2014.09.001
5. Daiber A, Di Lisa F, Oelze M, Kroller-Schon S, Steven S, Schulz E, Munzel T, Crosstalk of mitochondria with nadph oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function [published online ahead of print December 9, 2015]. Br J Pharmacol. doi: 10.1111/bph.13403. http://onlinelibrary.wiley.com/doi/10.1111/bph.13403/abstract;jsessionid=150E9A30F843D95F53F162452858D588.f04t04
6. Daiber A, Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 2010 1797 897 906. doi: 10.1016/j.bbabio.2010.01.032
7. Itani HA, Dikalova AE, McMaster WG, Nazarewicz RR, Bikineyeva AT, Harrison DG, Dikalov SI, Mitochondrial cyclophilin D in vascular oxidative stress and hypertension. Hypertension 2016 67 1218 1227. doi: 10.1161/HYPERTENSIONAHA.115.07085
8. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG, Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003 111 1201 1209. doi: 10.1172/JCI14172
9. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, Harrison DG, Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 2003 285 H2290 H2297. doi: 10.1152/ajpheart.00515.2003
10. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, Drexler H, Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007 27 943 948. doi: 10.1161/01.ATV.0000258415.32883.bf.
11. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI, Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 2010 107 106 116. doi: 10.1161/CIRCRESAHA.109.214601
12. Kröller-Schön S, Steven S, Kossmann S, Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal 2014 20 247 266. doi: 10.1089/ars.2012.4953
13. Wenzel P, Mollnau H, Oelze M, Schulz E, Wickramanayake JM, Müller J, Schuhmacher S, Hortmann M, Baldus S, Gori T, Brandes RP, Münzel T, Daiber A, First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal 2008 10 1435 1447. doi: 10.1089/ars.2007.1969
14. Doughan AK, Harrison DG, Dikalov SI, Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008 102 488 496. doi: 10.1161/CIRCRESAHA.107.162800
15. Drummond GR, Selemidis S, Griendling KK, Sobey CG, Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011 10 453 471. doi: 10.1038/nrd3403
16. Bedard K, Krause KH, The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007 87 245 313. doi: 10.1152/physrev.00044.2005
17. Brandes RP, Kreuzer J, Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 2005 65 16 27. doi: 10.1016/j.cardiores.2004.08.007
18. Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP, Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 2012 110 1217 1225. doi: 10.1161/CIRCRESAHA.112.267054
19. Lassègue B, Sorescu D, Szöcs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK, Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001 88 888 894
20. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR, The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res 2005 65 495 504. doi: 10.1016/j.cardiores.2004.10.026
21. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R, A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000 87 26 32
22. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M, Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004 109 227 233. doi: 10.1161/01.CIR.0000105680.92873.70
23. Xu H, Goettsch C, Xia N, Horke S, Morawietz H, Förstermann U, Li H, Differential roles of PKCalpha and PKCepsilon in controlling the gene expression of Nox4 in human endothelial cells. Free Radic Biol Med 2008 44 1656 1667. doi: 10.1016/j.freeradbiomed.2008.01.023
24. Fulton DJ, Barman SA, Clarity on the isoform-specific roles of NADPH oxidases and NADPH oxidase-4 in atherosclerosis. Arterioscler Thromb Vasc Biol 2016 36 579 581. doi: 10.1161/ATVBAHA.116.307096
25. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr., Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 2011 216 321 326. doi: 10.1016/j.atherosclerosis.2011.02.028
26. Gray SP, Di Marco E, Okabe J, NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013 127 1888 1902. doi: 10.1161/CIRCULATIONAHA.112.132159
27. Sobey CG, Judkins CP, Rivera J, Lewis CV, Diep H, Lee HW, Kemp-Harper BK, Broughton BR, Selemidis S, Gaspari TA, Samuel CS, Drummond GR, NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis. Free Radic Res 2015 49 186 198. doi: 10.3109/10715762.2014.992893
28. Gray SP, Di Marco E, Kennedy K, Chew P, Okabe J, El-Osta A, Calkin AC, Biessen EA, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA, Reactive oxygen species can provide atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling. Arterioscler Thromb Vasc Biol 2016 36 295 307. doi: 10.1161/ATVBAHA.115.307012
29. Quesada IM, Lucero A, Amaya C, Meijles DN, Cifuentes ME, Pagano PJ, Castro C, Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques. Atherosclerosis 2015 242 469 475. doi: 10.1016/j.atherosclerosis.2015.08.011
30. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC, Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000 20 1529 1535
31. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, Drummond GR, Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010 298 H24 H32. doi: 10.1152/ajpheart.00799.2009
32. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, Finkel T, Vascular effects following homozygous disruption of p47(phox): An essential component of NADPH oxidase. Circulation 2000 101 1234 1236
33. Barry-Lane PA, Patterson C, Van Der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS, p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001 108 1513 1522. doi: 10.1172/JCI11927
34. -/- mice. Cardiovasc Res 2012 94 20 29. doi: 10.1093/cvr/cvs026
35. Craige SM, Kant S, Reif M, Chen K, Pei Y, Angoff R, Sugamura K, Fitzgibbons T, Keaney JF Jr., Endothelial NADPH oxidase 4 protects ApoE-/- mice from atherosclerotic lesions. Free Radic Biol Med 2015 89 1 7. doi: 10.1016/j.freeradbiomed.2015.07.004
36. Schürmann C, Rezende F, Kruse C, Yasar Y, Löwe O, Fork C, Van de Sluis B, Bremer R, Weissmann N, Shah AM, Jo H, Brandes RP, Schröder K, The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J 2015 36 3447 3456. doi: 10.1093/eurheartj/ehv460
37. Langbein H, Brunssen C, Hofmann A, Cimalla P, Brux M, Bornstein SR, Deussen A, Koch E, Morawietz H, NADPH oxidase 4 protects against development of endothelial dysfunction and atherosclerosis in LDL receptor deficient mice. Eur Heart J 2016 37 1753 1761. doi: 10.1093/eurheartj/ehv564
38. Takac I, Schröder K, Zhang L, Lardy B, Anilkumar N, Lambeth JD, Shah AM, Morel F, Brandes RP, The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 2011 286 13304 13313. doi: 10.1074/jbc.M110.192138
39. Craige SM, Chen K, Pei Y, Li C, Huang X, Chen C, Shibata R, Sato K, Walsh K, Keaney JF Jr., NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011 124 731 740. doi: 10.1161/CIRCULATIONAHA.111.030775
40. Di Marco E, Gray SP, Kennedy K, Szyndralewiez C, Lyle AN, Lassègue B, Griendling KK, Cooper ME, Schmidt HH, Jandeleit-Dahm KA, NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis. Free Radic Biol Med 2016 97 556 567. doi: 10.1016/j.freeradbiomed.2016.07.013
41. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, Schmidt HH, Post-stroke inhibition of induced nadph oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010 8
42. Nishimura A, Ago T, Kuroda J, Arimura K, Tachibana M, Nakamura K, Wakisaka Y, Sadoshima J, Iihara K, Kitazono T, Detrimental role of pericyte Nox4 in the acute phase of brain ischemia. J Cereb Blood Flow Metab 2016 36 1143 1154. doi: 10.1177/0271678X15606456
43. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J, NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 2010 107 15565 15570. doi: 10.1073/pnas.1002178107
44. Maalouf RM, Eid AA, Gorin YC, Block K, Escobar GP, Bailey S, Abboud HE, Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am J Physiol Cell Physiol 2012 302 C597 C604. doi: 10.1152/ajpcell.00331.2011
45. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, Harrison DG, Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 2008 52 1803 1809. doi: 10.1016/j.jacc.2008.07.063
46. Yu P, Han W, Villar VA, Yang Y, Lu Q, Lee H, Li F, Quinn MT, Gildea JJ, Felder RA, Jose PA, Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells. Redox Biol 2014 2 570 579. doi: 10.1016/j.redox.2014.01.020
47. Holterman CE, Thibodeau JF, Towaij C, Gutsol A, Montezano AC, Parks RJ, Cooper ME, Touyz RM, Kennedy CR, Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol 2014 25 784 797. doi: 10.1681/ASN.2013040371
48. Montezano AC, Tsiropoulou S, Dulak-Lis M, Harvey A, Camargo Lde L, Touyz RM, Redox signaling, Nox5 and vascular remodeling in hypertension. Curr Opin Nephrol Hypertens 2015 24 425 433. doi: 10.1097/MNH.0000000000000153
49. Vendrov AE, Hakim ZS, Madamanchi NR, Rojas M, Madamanchi C, Runge MS, Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol 2007 27 2714 2721. doi: 10.1161/ATVBAHA.107.152629
50. Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T, Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 2008 275 3278 3289. doi: 10.1111/j.1742-4658.2008.06489.x.
51. Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, Tamura M, Kobayashi T, So A, Yamanaka Y, Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep 2014 4 4554. doi: 10.1038/srep04554
52. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA, Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 1996 93 8745 8749
53. Ohara Y, Peterson TE, Harrison DG, Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993 91 2546 2551. doi: 10.1172/JCI116491
54. Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, Panetta TF, Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 2001 88 188 91, A6
55. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, Channon KM, Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 2006 26 333 339. doi: 10.1161/01.ATV.0000196651.64776.51
56. Guthikonda S, Sinkey C, Barenz T, Haynes WG, Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003 107 416 421
57. Schröder K, Vecchione C, Jung O, Schreiber JG, Shiri-Sverdlov R, Van Gorp PJ, Busse R, Brandes RP, Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic Biol Med 2006 41 1353 1360. doi: 10.1016/j.freeradbiomed.2006.03.026
58. Wang Y, Wang GZ, Rabinovitch PS, Tabas I, Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages. Circ Res 2014 114 421 433. doi: 10.1161/CIRCRESAHA.114.302153
59. Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC, Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res 1992 275 169 180
60. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ, Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995 11 376 381. doi: 10.1038/ng1295-376
61. Nojiri H, Shimizu T, Funakoshi M, Yamaguchi O, Zhou H, Kawakami S, Ohta Y, Sami M, Tachibana T, Ishikawa H, Kurosawa H, Kahn RC, Otsu K, Shirasawa T, Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 2006 281 33789 33801. doi: 10.1074/jbc.M602118200
62. Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, Reuf J, Horaist C, Lebovitz R, Hunter GC, McIntyre K, Runge MS, Mitochondrial integrity and function in atherogenesis. Circulation 2002 106 544 549
63. Li H, Förstermann U, Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000 190 244 254. doi: 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8
64. Li H, Förstermann U, Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des 2009 15 3133 3145
65. Förstermann U, Sessa WC, Nitric oxide synthases: regulation and function. Eur Heart J 2012 33 829 37, 837a. doi: 10.1093/eurheartj/ehr304
66. Li H, Förstermann U, Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 2013 13 161 167. doi: 10.1016/j.coph.2013.01.006
67. Li H, Horke S, Förstermann U, Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 2013 34 313 319. doi: 10.1016/j.tips.2013.03.007
68. Förstermann U, Münzel T, Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006 113 1708 1714. doi: 10.1161/CIRCULATIONAHA.105.602532
69. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM, Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2004 24 445 450. doi: 10.1161/01.ATV.0000115637.48689.77
70. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hübschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Förstermann U, Ruetten H, Li H, Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 2008 325 370 379. doi: 10.1124/jpet.107.128009
71. Xia N, Daiber A, Habermeier A, Closs EI, Thum T, Spanier G, Lu Q, Oelze M, Torzewski M, Lackner KJ, Münzel T, Förstermann U, Li H, Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J Pharmacol Exp Ther 2010 335 149 154. doi: 10.1124/jpet.110.168724
72. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Lüscher T, Rabelink T, Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997 99 41 46. doi: 10.1172/JCI119131
73. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, Diesch J, Tousoulis D, Stefanadis C, Leeson P, Ratnatunga C, Pillai R, Channon KM, Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007 116 2851 2859. doi: 10.1161/CIRCULATIONAHA.107.704155
74. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, Jones DP, Hooper C, Taylor WR, Harrison D, Quyyumi AA, Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens 2008 22 401 407. doi: 10.1038/sj.jhh.1002329
75. Heitzer T, Krohn K, Albers S, Meinertz T, Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000 43 1435 1438. doi: 10.1007/s001250051551
76. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T, Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000 35 71 75
77. Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM, Xu H, Xia N, Kleschyov AL, Mang C, Warnholtz A, Münzel T, Förstermann U, Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther 2008 326 745 753. doi: 10.1124/jpet.108.139030
78. Goncharov NV, Avdonin PV, Nadeev AD, Zharkikh IL, Jenkins RO, Reactive oxygen species in pathogenesis of atherosclerosis. Curr Pharm Des 2015 21 1134 1146
79. McClelland S, Gawaz M, Kennerknecht E, Konrad CS, Sauer S, Schuerzinger K, Massberg S, Fitzgerald DJ, Belton O, Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 2009 202 84 91. doi: 10.1016/j.atherosclerosis.2008.04.016
80. Praticò D, Tillmann C, Zhang ZB, Li H, FitzGerald GA, Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 2001 98 3358 3363. doi: 10.1073/pnas.061607398
81. Hui Y, Ricciotti E, Crichton I, Yu Z, Wang D, Stubbe J, Wang M, Puré E, FitzGerald GA, Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 2010 121 2654 2660. doi: 10.1161/CIRCULATIONAHA.109.910687
82. Tang SY, Monslow J, Todd L, Lawson J, Puré E, FitzGerald GA, Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation 2014 129 1761 1769. doi: 10.1161/CIRCULATIONAHA.113.007913
83. Kirkby NS, Lundberg MH, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA, COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One 2014 9 e98165. doi: 10.1371/journal.pone.0098165
84. Faraci FM, Didion SP, Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004 24 1367 1373. doi: 10.1161/01.ATV.0000133604.20182.cf.
85. Fukai T, Ushio-Fukai M, Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011 15 1583 1606. doi: 10.1089/ars.2011.3999
86. Tribble DL, Gong EL, Leeuwenburgh C, Heinecke JW, Carlson EL, Verstuyft JG, Epstein CJ, Fatty streak formation in fat-fed mice expressing human copper-zinc superoxide dismutase. Arterioscler Thromb Vasc Biol 1997 17 1734 1740
87. Nelson SK, Bose SK, McCord JM, The toxicity of high-dose superoxide dismutase suggests that superoxide can both initiate and terminate lipid peroxidation in the reperfused heart. Free Radic Biol Med 1994 16 195 200
88. Yang H, Roberts LJ, Shi MJ, Zhou LC, Ballard BR, Richardson A, Guo ZM, Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res 2004 95 1075 1081. doi: 10.1161/01.RES.0000149564.49410.0d.
89. Strålin P, Karlsson K, Johansson BO, Marklund SL, The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995 15 2032 2036
90. Sentman ML, Brännström T, Westerlund S, Laukkanen MO, Ylä-Herttuala S, Basu S, Marklund SL, Extracellular superoxide dismutase deficiency and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2001 21 1477 1482
91. Tribble DL, Barcellos-Hoff MH, Chu BM, Gong EL, Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes. Arterioscler Thromb Vasc Biol 1999 19 1387 1392
92. Yang H, Zhou L, Wang Z, Roberts LJ 2nd, Lin X, Zhao Y, Guo Z, Overexpression of antioxidant enzymes in ApoE-deficient mice suppresses benzo(a)pyrene-accelerated atherosclerosis. Atherosclerosis 2009 207 51 58. doi: 10.1016/j.atherosclerosis.2009.03.052
93. de Haan JB, Witting PK, Stefanovic N, Pete J, Daskalakis M, Kola I, Stocker R, Smolich JJ, Lack of the antioxidant glutathione peroxidase-1 does not increase atherosclerosis in C57BL/J6 mice fed a high-fat diet. J Lipid Res 2006 47 1157 1167. doi: 10.1194/jlr.M500377-JLR200
94. Torzewski M, Ochsenhirt V, Kleschyov AL, Oelze M, Daiber A, Li H, Rossmann H, Tsimikas S, Reifenberg K, Cheng F, Lehr HA, Blankenberg S, Förstermann U, Münzel T, Lackner KJ, Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007 27 850 857. doi: 10.1161/01.ATV.0000258809.47285.07
95. Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB, Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 2007 115 2178 2187. doi: 10.1161/CIRCULATIONAHA.106.664250
96. Guo Z, Ran Q, Roberts LJ 2nd, Zhou L, Richardson A, Sharan C, Wu D, Yang H, Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med 2008 44 343 352. doi: 10.1016/j.freeradbiomed.2007.09.009
97. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM, Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002 106 484 490
98. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998 394 284 287. doi: 10.1038/28406
99. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST, Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab 2006 89 368 373. doi: 10.1016/j.ymgme.2006.07.004.
100. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST, Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 2006 281 29491 29500. doi: 10.1074/jbc.M605379200
101. Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman AM, Lusis AJ, Reddy ST, Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 2007 100 1200 1207. doi: 10.1161/01.RES.0000264499.48737.69
102. Zhang H, Luo Y, Zhang W, He Y, Dai S, Zhang R, Huang Y, Bernatchez P, Giordano FJ, Shadel G, Sessa WC, Min W, Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol 2007 170 1108 1120. doi: 10.2353/ajpath.2007.060960
103. Asmis R, Begley JG, Oxidized LDL promotes peroxide-mediated mitochondrial dysfunction and cell death in human macrophages: a caspase-3-independent pathway. Circ Res 2003 92 e20 e29
104. Lubos E, Loscalzo J, Handy DE, Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2011 15 1957 1997. doi: 10.1089/ars.2010.3586
105. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ, AtheroGene Investigators Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003 349 1605 1613. doi: 10.1056/NEJMoa030535
106. Cheng F, Torzewski M, Degreif A, Rossmann H, Canisius A, Lackner KJ, Impact of glutathione peroxidase-1 deficiency on macrophage foam cell formation and proliferation: implications for atherogenesis. PLoS One 2013 8 e72063. doi: 10.1371/journal.pone.0072063
107. Chew P, Yuen DY, Koh P, Stefanovic N, Febbraio MA, Kola I, Cooper ME, de Haan JB, Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. Arterioscler Thromb Vasc Biol 2009 29 823 830. doi: 10.1161/ATVBAHA.109.186619
108. Imai H, Nakagawa Y, Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 2003 34 145 169
109. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN, Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005 46 1239 1247. doi: 10.1194/jlr.M400511-JLR200
110. Mackness M, Mackness B, Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets 2013 17 829 837. doi: 10.1517/14728222.2013.790367
111. Aviram M, Vaya J, Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol 2013 24 339 344. doi: 10.1097/MOL.0b013e32835ffcfd
112. Costa LG, Cole TB, Furlong CE, Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomed 2005 76 Suppl 2 50 57
113. Mackness MI, Arrol S, Abbott C, Durrington PN, Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993 104 129 135
114. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST, Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001 276 44444 44449. doi: 10.1074/jbc.M105660200
115. Witte I, Foerstermann U, Devarajan A, Reddy ST, Horke S, Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J Lipids 2012 2012 342806. doi: 10.1155/2012/342806
116. Horke S, Witte I, Wilgenbus P, Krüger M, Strand D, Förstermann U, Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007 115 2055 2064. doi: 10.1161/CIRCULATIONAHA.106.681700
117. Hagmann H, Kuczkowski A, Ruehl M, Lamkemeyer T, Brodesser S, Horke S, Dryer S, Schermer B, Benzing T, Brinkkoetter PT, Breaking the chain at the membrane: paraoxonase 2 counteracts lipid peroxidation at the plasma membrane. FASEB J 2014 28 1769 1779. doi: 10.1096/fj.13-240309
118. Fortunato G, Di Taranto MD, Bracale UM, Del Guercio L, Carbone F, Mazzaccara C, Morgante A, D'Armiento FP, D'Armiento M, Porcellini M, Sacchetti L, Bracale G, Salvatore F, Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008 28 594 600. doi: 10.1161/ATVBAHA.107.154658
119. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN, Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000 275 33435 33442. doi: 10.1074/jbc.M004543200
120. Schweikert EM, Devarajan A, Witte I, Wilgenbus P, Amort J, Förstermann U, Shabazian A, Grijalva V, Shih DM, Farias-Eisner R, Teiber JF, Reddy ST, Horke S, PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ 2012 19 1549 1560. doi: 10.1038/cdd.2012.35
121. Altenhöfer S, Witte I, Teiber JF, Wilgenbus P, Pautz A, Li H, Daiber A, Witan H, Clement AM, Förstermann U, Horke S, One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem 2010 285 24398 24403. doi: 10.1074/jbc.M110.118604
122. Marsillach J, Camps J, Beltran-Debón R, Rull A, Aragones G, Maestre-Martínez C, Sabench F, Hernández M, Castillo DD, Joven J, Mackness M, Mackness B, Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin Invest 2011 41 308 314. doi: 10.1111/j.1365-2362.2010.02411.x.
123. Hanschmann EM, Godoy JR, Berndt C, Hudemann C, Lillig CH, Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signal 2013 19 1539 1605. doi: 10.1089/ars.2012.4599
124. Huang Q, Zhou HJ, Zhang H, Huang Y, Hinojosa-Kirschenbaum F, Fan P, Yao L, Belardinelli L, Tellides G, Giordano FJ, Budas GR, Min W, Thioredoxin-2 inhibits mitochondrial reactive oxygen species generation and apoptosis stress kinase-1 activity to maintain cardiac function. Circulation 2015 131 1082 1097. doi: 10.1161/CIRCULATIONAHA.114.012725
125. Kirsch J, Schneider H, Pagel JI, Endothelial Dysfunction, and A Prothrombotic, Proinflammatory Phenotype Is Caused by Loss of Mitochondrial Thioredoxin Reductase in Endothelium. Arterioscler Thromb Vasc Biol 2016 36 1891 1899. doi: 10.1161/ATVBAHA.116.307843
126. Liu VW, Huang PL, Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 2008 77 19 29. doi: 10.1016/j.cardiores.2007.06.024
127. Schwarz PM, Kleinert H, Förstermann U, Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. Arterioscler Thromb Vasc Biol 1999 19 2584 2590
128. Tsutsui M, Neuronal nitric oxide synthase as a novel anti-atherogenic factor. J Atheroscler Thromb 2004 11 41 48
129. Schödel J, Padmapriya P, Marx A, Huang PL, Ertl G, Kuhlencordt PJ, Expression of neuronal nitric oxide synthase splice variants in atherosclerotic plaques of apoE knockout mice. Atherosclerosis 2009 206 383 389. doi: 10.1016/j.atherosclerosis.2009.02.033
130. Capettini LS, Cortes SF, Silva JF, Alvarez-Leite JI, Lemos VS, Decreased production of neuronal NOS-derived hydrogen peroxide contributes to endothelial dysfunction in atherosclerosis. Br J Pharmacol 2011 164 1738 1748. doi: 10.1111/j.1476-5381.2011.01500.x.
131. Benkhoff S, Loot AE, Pierson I, Sturza A, Kohlstedt K, Fleming I, Shimokawa H, Grisk O, Brandes RP, Schröder K, Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. Arterioscler Thromb Vasc Biol 2012 32 1605 1612. doi: 10.1161/ATVBAHA.112.251140
132. Sanz MJ, Hickey MJ, Johnston B, McCafferty DM, Raharjo E, Huang PL, Kubes P, Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice. Br J Pharmacol 2001 134 305 312. doi: 10.1038/sj.bjp.0704234
133. Talukder MA, Fujiki T, Morikawa K, Motoishi M, Kubota H, Morishita T, Tsutsui M, Takeshita A, Shimokawa H, Up-regulated neuronal nitric oxide synthase compensates coronary flow response to bradykinin in endothelial nitric oxide synthase-deficient mice. J Cardiovasc Pharmacol 2004 44 437 445
134. Seddon MD, Chowienczyk PJ, Brett SE, Casadei B, Shah AM, Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo. Circulation 2008 117 1991 1996. doi: 10.1161/CIRCULATIONAHA.107.744540
135. Seddon M, Melikian N, Dworakowski R, Shabeeh H, Jiang B, Byrne J, Casadei B, Chowienczyk P, Shah AM, Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo. Circulation 2009 119 2656 2662. doi: 10.1161/CIRCULATIONAHA.108.822205
136. Morishita T, Tsutsui M, Shimokawa H, Horiuchi M, Tanimoto A, Suda O, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N, Nakashima Y, Vasculoprotective roles of neuronal nitric oxide synthase. FASEB J 2002 16 1994 1996. doi: 10.1096/fj.02-0155fje
137. Kuhlencordt PJ, Hötten S, Schödel J, Rützel S, Hu K, Widder J, Marx A, Huang PL, Ertl G, Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol 2006 26 1539 1544. doi: 10.1161/01.ATV.0000223143.88128.19
138. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL, Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001 103 3099 3104
139. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL, Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001 104 448 454
140. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL, Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001 104 2391 2394
141. Ponnuswamy P, Schröttle A, Ostermeier E, Grüner S, Huang PL, Ertl G, Hoffmann U, Nieswandt B, Kuhlencordt PJ, eNOS protects from atherosclerosis despite relevant superoxide production by the enzyme in apoE mice. PLoS One 2012 7 e30193. doi: 10.1371/journal.pone.0030193
142. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M, Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002 110 331 340. doi: 10.1172/JCI15215
143. Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, Inoue N, Yada T, Goto M, Fukatsu A, Hayashi T, Alp NJ, Channon KM, Yokoyama M, Kawashima S, A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol 2007 27 1632 1637. doi: 10.1161/ATVBAHA.107.142182
144. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H, Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010 23 75 93. doi: 10.1016/j.niox.2010.04.007
145. Gunnett CA, Lund DD, McDowell AK, Faraci FM, Heistad DD, Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005 25 1617 1622. doi: 10.1161/01.ATV.0000172626.00296.ba.
146. Xia Y, Zweier JL, Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci U S A 1997 94 6954 6958
147. Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossi F, Giugliano D, D'Amico M, Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 2004 53 454 462
148. Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S, Bernardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M, Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005 312 945 953. doi: 10.1124/jpet.104.077644
149. Depre C, Havaux X, Renkin J, Vanoverschelde JL, Wijns W, Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque. Cardiovasc Res 1999 41 465 472
150. Pacher P, Beckman JS, Liaudet L, Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007 87 315 424. doi: 10.1152/physrev.00029.2006
151. Liaudet L, Rosenblatt-Velin N, Pacher P, Role of peroxynitrite in the cardiovascular dysfunction of septic shock. Curr Vasc Pharmacol 2013 11 196 207
152. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA, Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997 17 2479 2488
153. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM, Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999 19 646 655
154. Hare JM, Stamler JS, NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005 115 509 517. doi: 10.1172/JCI24459
155. Xia N, Li H, The role of perivascular adipose tissue in obesity-induced vascular dysfunction [published online ahead of print October 20, 2016]. Br J Pharmacol. doi: 10.1111/bph.13650. http://onlinelibrary.wiley.com/doi/10.1111/bph.13650/abstract
156. Xia N, Horke S, Habermeier A, Closs EI, Reifenberg G, Gericke A, Mikhed Y, Münzel T, Daiber A, Förstermann U, Li H, Uncoupling of endothelial nitric oxide synthase in perivascular adipose tissue of diet-induced obese mice. Arterioscler Thromb Vasc Biol 2016 36 78 85. doi: 10.1161/ATVBAHA.115.306263
157. Bentzon JF, Falk E, Atherosclerotic lesions in mouse and man: is it the same disease? Curr Opin Lipidol 2010 21 434 440. doi: 10.1097/MOL.0b013e32833ded6a.
158. Gleissner CA, Translational atherosclerosis research: From experimental models to coronary artery disease in humans. Atherosclerosis 2016 248 110 116. doi: 10.1016/j.atherosclerosis.2016.03.013
159. Matoba T, Sato K, Egashira K, Mouse models of plaque rupture. Curr Opin Lipidol 2013 24 419 425. doi: 10.1097/MOL.0b013e3283646e4d.
160. Sato K, Nakano K, Katsuki S, Matoba T, Osada K, Sawamura T, Sunagawa K, Egashira K, Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe. J Atheroscler Thromb 2012 19 986 998
161. Van Der Donckt C, Van Herck JL, Schrijvers DM, Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur Heart J 2015 36 1049 1058. doi: 10.1093/eurheartj/ehu041
162. Getz GS, Reardon CA, Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis? Arterioscler Thromb Vasc Biol 2016 36 1734 1741. doi: 10.1161/ATVBAHA.116.306874
163. Miller AA, De Silva TM, Jackman KA, Sobey CG, Effect of gender and sex hormones on vascular oxidative stress. Clin Exp Pharmacol Physiol 2007 34 1037 1043. doi: 10.1111/j.1440-1681.2007.04732.x.
164. Joakimsen O, Bonaa KH, Stensland-Bugge E, Jacobsen BK, Age and sex differences in the distribution and ultrasound morphology of carotid atherosclerosis: the Tromsø Study. Arterioscler Thromb Vasc Biol 1999 19 3007 3013
165. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M, Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005 45 545 551. doi: 10.1161/01.HYP.0000157409.88971.fc.
166. Miller AA, Drummond GR, Mast AE, Schmidt HH, Sobey CG, Effect of gender on NADPH-oxidase activity, expression, and function in the cerebral circulation: role of estrogen. Stroke 2007 38 2142 2149. doi: 10.1161/STROKEAHA.106.477406
167. Laughlin MH, Welshons WV, Sturek M, Rush JW, Turk JR, Taylor JA, Judy BM, Henderson KK, Ganjam VK, Gender, exercise training, and eNOS expression in porcine skeletal muscle arteries. J Appl Physiol (1985) 2003 95 250 264. doi: 10.1152/japplphysiol.00061.2003
168. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Förstermann U, Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998 31 582 588
169. Nikpay M, Goel A, Won HH, CARDIoGRAMplusC4D Consortium A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015 47 1121 1130. doi: 10.1038/ng.3396
170. Nurnberg ST, Zhang H, Hand NJ, Bauer RC, Saleheen D, Reilly MP, Rader DJ, From loci to biology: functional genomics of genome-wide association for coronary disease. Circ Res 2016 118 586 606. doi: 10.1161/CIRCRESAHA.115.306464
171. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M, Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998 97 135 137
172. Shimokata K, Yamada Y, Kondo T, Ichihara S, Izawa H, Nagata K, Murohara T, Ohno M, Yokota M, Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 2004 172 167 173
173. Arca M, Conti B, Montali A, Pignatelli P, Campagna F, Barillà F, Tanzilli G, Verna R, Vestri A, Gaudio C, Violi F, C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol 2008 28 752 757. doi: 10.1161/ATVBAHA.107.154823
174. Cahilly C, Ballantyne CM, Lim DS, Gotto A, Marian AJ, A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 2000 86 391 395
175. Andreassi MG, Adlerstein D, Carpeggiani C, Shehi E, Fantinato S, Ghezzi E, Botto N, Coceani M, L'abbate A, Individual and summed effects of high-risk genetic polymorphisms on recurrent cardiovascular events following ischemic heart disease. Atherosclerosis 2012 223 409 415. doi: 10.1016/j.atherosclerosis.2012.05.029
176. Neves AL, Mohammedi K, Emery N, Roussel R, Fumeron F, Marre M, Velho G, Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in type 2 diabetic subjects. Mol Genet Metab 2012 106 359 365. doi: 10.1016/j.ymgme.2012.04.023
177. Kakko S, Päivänsalo M, Koistinen P, Kesäniemi YA, Kinnula VL, Savolainen MJ, The signal sequence polymorphism of the MnSOD gene is associated with the degree of carotid atherosclerosis. Atherosclerosis 2003 168 147 152
178. Fujimoto H, Taguchi J, Imai Y, Ayabe S, Hashimoto H, Kobayashi H, Ogasawara K, Aizawa T, Yamakado M, Nagai R, Ohno M, Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur Heart J 2008 29 1267 1274. doi: 10.1093/eurheartj/ehm500
179. Möllsten A, Jorsal A, Lajer M, Vionnet N, Tarnow L, The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia 2009 52 2590 2593. doi: 10.1007/s00125-009-1550-1
180. Marklund SL, Nilsson P, Israelsson K, Schampi I, Peltonen M, Asplund K, Two variants of extracellular-superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle-aged population. J Intern Med 1997 242 5 14
181. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, Jensen G, Nordestgaard BG, Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 2004 109 59 65. doi: 10.1161/01.CIR.0000105720.28086.6C.
182. Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, Shimomura H, Sakagashira S, Nishi M, Sasaki H, Sanke T, Nanjo K, Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. Diabetes 2004 53 2455 2460
183. Heslop CL, Tebbutt SJ, Podder M, Ruan J, Hill JS, Combined polymorphisms in oxidative stress genes predict coronary artery disease and oxidative stress in coronary angiography patients. Ann Hum Genet 2012 76 435 447. doi: 10.1111/j.1469-1809.2012.00731.x.
184. Nemoto M, Nishimura R, Sasaki T, Hiki Y, Miyashita Y, Nishioka M, Fujimoto K, Sakuma T, Ohashi T, Fukuda K, Eto Y, Tajima N, Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovasc Diabetol 2007 6 23. doi: 10.1186/1475-2840-6-23
185. Najafi M, Ghasemi H, Roustazadeh A, Farajollahi M, Lack of association between glutathione peroxidase1 (GPx1) activity, Pro198Leu polymorphism and stenosis of coronary arteries: A population-based prediction. Meta Gene 2014 2 722 729. doi: 10.1016/j.mgene.2014.09.007
186. Souiden Y, Mallouli H, Meskhi S, Chaabouni Y, Rebai A, Chéour F, Mahdouani K, MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity. Biol Res 2016 49 22. doi: 10.1186/s40659-016-0083-6
187. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD, Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 2006 164 921 935. doi: 10.1093/aje/kwj302
188. Casas JP, Bautista LE, Humphries SE, Hingorani AD, Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004 109 1359 1365. doi: 10.1161/01.CIR.0000121357.76910.A3
189. Rai H, Parveen F, Kumar S, Kapoor A, Sinha N, Association of endothelial nitric oxide synthase gene polymorphisms with coronary artery disease: an updated meta-analysis and systematic review. PLoS One 2014 9 e113363. doi: 10.1371/journal.pone.0113363
190. Liu D, Jiang Z, Dai L, Zhang X, Yan C, Han Y, Association between the-786T>C 1polymorphism in the promoter region of endothelial nitric oxide synthase (eNOS) and risk of coronary artery disease: a systematic review and meta-analysis. Gene 2014 545 175 183. doi: 10.1016/j.gene.2013.09.099
191. San José G, Fortuño A, Beloqui O, Díez J, Zalba G, NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci (Lond) 2008 114 173 182. doi: 10.1042/CS20070130
192. Wyche KE, Wang SS, Griendling KK, Dikalov SI, Austin H, Rao S, Fink B, Harrison DG, Zafari AM, C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004 43 1246 1251. doi: 10.1161/01.HYP.0000126579.50711.62
193. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM, Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000 102 1744 1747
194. Wu Z, Lou Y, Jin W, Liu Y, Lu L, Chen Q, Xie Y, Lu G, Relationship of the p22phox (CYBA) gene polymorphism C242T with risk of coronary artery disease: a meta-analysis. PLoS One 2013 8 e70885. doi: 10.1371/journal.pone.0070885
195. Xu Q, Yuan F, Shen X, Wen H, Li W, Cheng B, Wu J, Polymorphisms of C242T and A640G in CYBA gene and the risk of coronary artery disease: a meta-analysis. PLoS One 2014 9 e84251. doi: 10.1371/journal.pone.0084251
196. Violi F, Sanguigni V, Carnevale R, Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009 120 1616 1622. doi: 10.1161/CIRCULATIONAHA.109.877191
197. Loukogeorgakis SP, Van den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee B, de Groot E, MacAllister RJ, Kuijpers TW, Deanfield JE, Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 2010 121 2310 2316. doi: 10.1161/CIRCULATIONAHA.108.814731
198. Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, Loffredo L, Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 2013 33 406 412. doi: 10.1161/ATVBAHA.112.300438
199. Sibley CT, Estwick T, Zavodni A, Assessment of atherosclerosis in chronic granulomatous disease. Circulation 2014 130 2031 2039. doi: 10.1161/CIRCULATIONAHA.113.006824
200. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK, Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002 105 1429 1435
201. Mohammedi K, Bellili-Muñoz N, Marklund SL, Driss F, Le Nagard H, Patente TA, Fumeron F, Roussel R, Hadjadj S, Marre M, Velho G, Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovasc Diabetol 2015 14 845. doi: 10.1186/s12933-014-0163-2
202. Sandström J, Nilsson P, Karlsson K, Marklund SL, 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem 1994 269 19163 19166
203. Adachi T, Yamada H, Yamada Y, Morihara N, Yamazaki N, Murakami T, Futenma A, Kato K, Hirano K, Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface. Biochem J 1996 313 (Pt 1) 235 239
204. Chu Y, Alwahdani A, Iida S, Lund DD, Faraci FM, Heistad DD, Vascular effects of the human extracellular superoxide dismutase R213G variant. Circulation 2005 112 1047 1053. doi: 10.1161/CIRCULATIONAHA.104.531251
205. Hartney JM, Stidham T, Goldstrohm DA, A common polymorphism in extracellular superoxide dismutase affects cardiopulmonary disease risk by altering protein distribution. Circ Cardiovasc Genet 2014 7 659 666. doi: 10.1161/CIRCGENETICS.113.000504
206. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, Albanes D, Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000 60 6381 6383
207. Zhang JX, Wang ZM, Zhang JJ, Zhu LL, Gao XF, Chen SL, Association of glutathione peroxidase-1 (GPx-1) rs1050450 Pro198Leu and Pro197Leu polymorphisms with cardiovascular risk: a meta-analysis of observational studies. J Geriatr Cardiol 2014 11 141 150. doi: 10.3969/j.issn.1671-5411.2014.02.003
208. Forsberg L, de Faire U, Marklund SL, Andersson PM, Stegmayr B, Morgenstern R, Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1. Blood Cells Mol Dis 2000 26 423 426. doi: 10.1006/bcmd.2000.0325
209. Vecoli C, Endothelial nitric oxide synthase gene polymorphisms in cardiovascular disease. Vitam Horm 2014 96 387 406. doi: 10.1016/B978-0-12-800254-4.00015-5
210. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J, Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 2000 97 2832 2835
211. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, Mourad M, Horie S, Feron O, Balligand JL, Wattiez R, Pirson Y, Chauveau D, Lens XM, Devuyst O, Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002 11 229 241
212. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC, Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)->Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001 276 26674 26679. doi: 10.1074/jbc.M103647200
213. McDonald DM, Alp NJ, Channon KM, Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics 2004 14 831 839
214. Joshi MS, Mineo C, Shaul PW, Bauer JA, Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 2007 21 2655 2663. doi: 10.1096/fj.06-7088com
215. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O'Shaughnessy KM, Brown MJ, A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999 100 1515 1520
216. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE, A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996 2 41 45
217. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, Biagini A, Clerico A, Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003 49 389 395
218. Karvonen J, Kauma H, Kervinen K, Rantala M, Ikäheimo M, Päivänsalo M, Savolainen MJ, Kesäniemi YA, Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort. J Intern Med 2002 251 102 110
219. Granath B, Taylor RR, Van Bockxmeer FM, Mamotte CD, Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J Cardiovasc Risk 2001 8 235 241
220. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, Yabe-Nishimura C, Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005 112 2677 2685. doi: 10.1161/CIRCULATIONAHA.105.573709
221. Li H, Witte K, August M, Brausch I, Gödtel-Armbrust U, Habermeier A, Closs EI, Oelze M, Münzel T, Förstermann U, Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006 47 2536 2544. doi: 10.1016/j.jacc.2006.01.071
222. Chalupsky K, Cai H, Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2005 102 9056 9061. doi: 10.1073/pnas.0409594102
223. Demougeot C, Prigent-Tessier A, Bagnost T, André C, Guillaume Y, Bouhaddi M, Marie C, Berthelot A, Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci 2007 80 1128 1134. doi: 10.1016/j.lfs.2006.12.003
224. Rodriguez S, Richert L, Berthelot A, Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 2000 22 75 85
225. Johnson FK, Johnson RA, Peyton KJ, Durante W, Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2005 288 R1057 R1062. doi: 10.1152/ajpregu.00758.2004
226. Galougahi KK, Liu CC, Gentile C, Kok C, Nunez A, Garcia A, Fry NA, Davies MJ, Hawkins CL, Rasmussen HH, Figtree GA, Glutathionylation mediates angiotensin II-induced eNOS uncoupling, amplifying NADPH oxidase-dependent endothelial dysfunction. J Am Heart Assoc 2014 3 e000731. doi: 10.1161/JAHA.113.000731
227. Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB, Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995 77 510 518
228. Stepp DW, Ou J, Ackerman AW, Welak S, Klick D, Pritchard KA Jr., Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ. Am J Physiol Heart Circ Physiol 2002 283 H750 H759. doi: 10.1152/ajpheart.00029.2002
229. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M, Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999 100 2131 2134
230. Ryoo S, Gupta G, Benjo A, Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008 102 923 932. doi: 10.1161/CIRCRESAHA.107.169573
231. Erdely A, Kepka-Lenhart D, Salmen-Muniz R, Chapman R, Hulderman T, Kashon M, Simeonova PP, Morris SM Jr., Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One 2010 5 e15253. doi: 10.1371/journal.pone.0015253
232. Hayashi T, Esaki T, Sumi D, Mukherjee T, Iguchi A, Chaudhuri G, Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism. Proc Natl Acad Sci U S A 2006 103 10485 10490. doi: 10.1073/pnas.0603918103
233. Vaisman BL, Andrews KL, Khong SM, Wood KC, Moore XL, Fu Y, Kepka-Lenhart DM, Morris SM Jr, Remaley AT, Chin-Dusting JP, Selective endothelial overexpression of arginase II induces endothelial dysfunction and hypertension and enhances atherosclerosis in mice. PLoS One 2012 7 e39487. doi: 10.1371/journal.pone.0039487
234. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL, Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999 103 897 905. doi: 10.1172/JCI4829
235. Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM, Dimmeler S, Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation 2001 103 2102 2107
236. Steffen Y, Jung T, Klotz LO, Schewe T, Grune T, Sies H, Protein modification elicited by oxidized low-density lipoprotein (LDL) in endothelial cells: protection by (-)-epicatechin. Free Radic Biol Med 2007 42 955 970. doi: 10.1016/j.freeradbiomed.2006.12.024
237. Jaimes EA, DeMaster EG, Tian RX, Raij L, Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler Thromb Vasc Biol 2004 24 1031 1036. doi: 10.1161/01.ATV.0000127083.88549.58
238. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, Ungvari Z, Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009 297 H13 H20. doi: 10.1152/ajpheart.00368.2009
239. Steffen Y, Vuillaume G, Stolle K, Roewer K, Lietz M, Schueller J, Lebrun S, Wallerath T, Cigarette smoke and LDL cooperate in reducing nitric oxide bioavailability in endothelial cells via effects on both eNOS and NADPH oxidase. Nitric Oxide 2012 27 176 184. doi: 10.1016/j.niox.2012.06.006
240. Giacco F, Brownlee M, Oxidative stress and diabetic complications. Circ Res 2010 107 1058 1070. doi: 10.1161/CIRCRESAHA.110.223545
241. Funk DM, Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012 2012 460 465. doi: 10.1182/asheducation-2012.1.460
242. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T, Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001 88 E14 E22
243. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, Goh N, Rockett KA, Channon KM, Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 2003 112 725 735. doi: 10.1172/JCI17786
244. Faria AM, Papadimitriou A, Silva KC, Lopes de Faria JM, Lopes de Faria JB, Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels. Diabetes 2012 61 1838 1847. doi: 10.2337/db11-1241
245. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, Thum T, Bauersachs J, Ertl G, Zou MH, Förstermann U, Münzel T, Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008 198 65 76. doi: 10.1016/j.atherosclerosis.2007.10.003
246. Xu J, Wu Y, Song P, Zhang M, Wang S, Zou MH, Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 2007 116 944 953. doi: 10.1161/CIRCULATIONAHA.106.684795
247. Schuhmacher S, Oelze M, Bollmann F, Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011 60 2608 2616. doi: 10.2337/db10-1395
248. Pannirselvam M, Simon V, Verma S, Anderson T, Triggle CR, Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol 2003 140 701 706. doi: 10.1038/sj.bjp.0705476
249. Pannirselvam M, Verma S, Anderson TJ, Triggle CR, Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 2002 136 255 263. doi: 10.1038/sj.bjp.0704683
250. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A, Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000 87 566 573
251. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW, Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008 102 95 102. doi: 10.1161/CIRCRESAHA.107.155028
252. Yao L, Chandra S, Toque HA, Bhatta A, Rojas M, Caldwell RB, Caldwell RW, Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 2013 97 509 519. doi: 10.1093/cvr/cvs371
253. Giri H, Muthuramu I, Dhar M, Rathnakumar K, Ram U, Dixit M, Protein tyrosine phosphatase SHP2 mediates chronic insulin-induced endothelial inflammation. Arterioscler Thromb Vasc Biol 2012 32 1943 1950. doi: 10.1161/ATVBAHA.111.239251
254. Romero MJ, Iddings JA, Platt DH, Ali MI, Cederbaum SD, Stepp DW, Caldwell RB, Caldwell RW, Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 2012 302 H159 H166. doi: 10.1152/ajpheart.00774.2011
255. Toque HA, Tostes RC, Yao L, Xu Z, Webb RC, Caldwell RB, Caldwell RW, Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med 2011 8 722 733. doi: 10.1111/j.1743-6109.2010.02098.x.
256. Grönros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J, Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 2011 300 H1174 H1181. doi: 10.1152/ajpheart.00560.2010
257. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA, Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 2008 31 134 139. doi: 10.2337/dc07-1198
258. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z, Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol 2011 300 H777 H783. doi: 10.1152/ajpheart.00831.2010
259. Shemyakin A, Kövamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, Jung C, Pernow J, Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 2012 126 2943 2950. doi: 10.1161/CIRCULATIONAHA.112.140335
260. Kwak BR, Bäck M, Bochaton-Piallat ML, Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J 2014 35 3013 20, 3020a. doi: 10.1093/eurheartj/ehu353
261. Cheng C, Tempel D, Van Haperen R, Van Der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R, Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006 113 2744 2753. doi: 10.1161/CIRCULATIONAHA.105.590018
262. Cheng C, Van Haperen R, de Waard M, Van Damme LC, Tempel D, Hanemaaijer L, Van Cappellen GW, Bos J, Slager CJ, Duncker DJ, Van Der Steen AF, de Crom R, Krams R, Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. Blood 2005 106 3691 3698. doi: 10.1182/blood-2005-06-2326
263. Nam D, Ni CW, Rezvan A, Suo J, Budzyn K, Llanos A, Harrison D, Giddens D, Jo H, Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol 2009 297 H1535 H1543. doi: 10.1152/ajpheart.00510.2009
264. Chen YC, Bui AV, Diesch J, Manasseh R, Hausding C, Rivera J, Haviv I, Agrotis A, Htun NM, Jowett J, Hagemeyer CE, Hannan RD, Bobik A, Peter K, A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ Res 2013 113 252 265. doi: 10.1161/CIRCRESAHA.113.301562
265. Hopkins PN, Molecular biology of atherosclerosis. Physiol Rev 2013 93 1317 1542. doi: 10.1152/physrev.00004.2012
266. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH, Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007 49 2379 2393. doi: 10.1016/j.jacc.2007.02.059
267. Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, Orisio S, Remuzzi G, Remuzzi A, Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 1995 76 536 543
268. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM, Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999 399 601 605. doi: 10.1038/21224
269. Gallis B, Corthals GL, Goodlett DR, Ueba H, Kim F, Presnell SR, Figeys D, Harrison DG, Berk BC, Aebersold R, Corson MA, Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J Biol Chem 1999 274 30101 30108
270. Fleming I, Molecular mechanisms underlying the activation of eNOS. Pflugers Arch 2010 459 793 806. doi: 10.1007/s00424-009-0767-7
271. Lam CF, Peterson TE, Richardson DM, Croatt AJ, d'Uscio LV, Nath KA, Katusic ZS, Increased blood flow causes coordinated upregulation of arterial eNOS and biosynthesis of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol 2006 290 H786 H793. doi: 10.1152/ajpheart.00759.2005
272. Gambillara V, Chambaz C, Montorzi G, Roy S, Stergiopulos N, Silacci P, Plaque-prone hemodynamics impair endothelial function in pig carotid arteries. Am J Physiol Heart Circ Physiol 2006 290 H2320 H2328. doi: 10.1152/ajpheart.00486.2005
273. Ziegler T, Bouzourène K, Harrison VJ, Brunner HR, Hayoz D, Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol 1998 18 686 692
274. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, Griendling KK, Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ Res 1998 82 1094 1101
275. Hwang J, Ing MH, Salazar A, Lassègue B, Griendling K, Navab M, Sevanian A, Hsiai TK, Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ Res 2003 93 1225 1232. doi: 10.1161/01.RES.0000104087.29395.66
276. Harris CM, Sanders SA, Massey V, Role of the flavin midpoint potential and NAD binding in determining NAD versus oxygen reactivity of xanthine oxidoreductase. J Biol Chem 1999 274 4561 4569
277. Lima B, Forrester MT, Hess DT, Stamler JS, S-nitrosylation in cardiovascular signaling. Circ Res 2010 106 633 646. doi: 10.1161/CIRCRESAHA.109.207381
278. Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR, Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res 2007 75 349 358. doi: 10.1016/j.cardiores.2007.03.030
279. Ravi K, Brennan LA, Levic S, Ross PA, Black SM, S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci U S A 2004 101 2619 2624
280. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G, McMahon TJ, Dickfeld T, Marshall HE, Que LG, Stamler JS, Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 2004 116 617 628
281. Song P, Zou MH, Redox regulation of endothelial cell fate. Cell Mol Life Sci 2014 71 3219 3239. doi: 10.1007/s00018-014-1598-z.
282. King AL, Polhemus DJ, Bhushan S, Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A 2014 111 3182 3187. doi: 10.1073/pnas.1321871111
283. Wang R, Szabo C, Ichinose F, Ahmed A, Whiteman M, Papapetropoulos A, The role of H2S bioavailability in endothelial dysfunction. Trends Pharmacol Sci 2015 36 568 578. doi: 10.1016/j.tips.2015.05.007
284. Yuan S, Patel RP, Kevil CG, Working with nitric oxide and hydrogen sulfide in biological systems. Am J Physiol Lung Cell Mol Physiol 2015 308 L403 L415. doi: 10.1152/ajplung.00327.2014
285. Altaany Z, Ju Y, Yang G, Wang R, The coordination of S-sulfhydration, S-nitrosylation, and phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide. Sci Signal 2014 7 ra87. doi: 10.1126/scisignal.2005478
286. Chung HS, Wang SB, Venkatraman V, Murray CI, Van Eyk JE, Cysteine oxidative posttranslational modifications: emerging regulation in the cardiovascular system. Circ Res 2013 112 382 392. doi: 10.1161/CIRCRESAHA.112.268680
287. Brown DI, Griendling KK, Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 2015 116 531 549. doi: 10.1161/CIRCRESAHA.116.303584
288. Wadham C, Parker A, Wang L, Xia P, High glucose attenuates protein S-nitrosylation in endothelial cells: role of oxidative stress. Diabetes 2007 56 2715 2721. doi: 10.2337/db06-1294
289. Steffensen LB, Mortensen MB, Kjolby M, Hagensen MK, Oxvig C, Bentzon JF, Disturbed Laminar Blood Flow Vastly Augments Lipoprotein Retention in the Artery Wall: A Key Mechanism Distinguishing Susceptible From Resistant Sites. Arterioscler Thromb Vasc Biol 2015 35 1928 1935. doi: 10.1161/ATVBAHA.115.305874
290. Peiffer V, Sherwin SJ, Weinberg PD, Does low and oscillatory wall shear stress correlate spatially with early atherosclerosis? A systematic review. Cardiovasc Res 2013 99 242 250. doi: 10.1093/cvr/cvt044
291. Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS, Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation 2008 117 2919 2927. doi: 10.1161/CIRCULATIONAHA.107.754614
292. Von Der Thüsen JH, Van Berkel TJ, Biessen EA, Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001 103 1164 1170
293. Wight TN, Merrilees MJ, Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004 94 1158 1167. doi: 10.1161/01.RES.0000126921.29919.51
294. Mangat R, Warnakula S, Borthwick F, Hassanali Z, Uwiera RR, Russell JC, Cheeseman CI, Vine DF, Proctor SD, Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat. J Am Heart Assoc 2012 1 e003434. doi: 10.1161/JAHA.112.003434
295. Ballinger ML, Osman N, Hashimura K, de Haan JB, Jandeleit-Dahm K, Allen T, Tannock LR, Rutledge JC, Little PJ, Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med 2010 14 1408 1418. doi: 10.1111/j.1582-4934.2009.00902.x.
296. Osman N, Getachew R, Thach L, Wang H, Su X, Zheng W, Little PJ, Platelet-derived growth factor-stimulated versican synthesis but not glycosaminoglycan elongation in vascular smooth muscle is mediated via Akt phosphorylation. Cell Signal 2014 26 912 916. doi: 10.1016/j.cellsig.2014.01.019
297. Meyers CD, Tannock LR, Wight TN, Chait A, Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res 2003 44 2152 2160. doi: 10.1194/jlr.M300252-JLR200
298. Cardona-Sanclemente LE, Born GV, Effect of inhibition of nitric oxide synthesis on the uptake of LDL and fibrinogen by arterial walls and other organs of the rat. Br J Pharmacol 1995 114 1490 1494
299. Weinberg PD, Rate-limiting steps in the development of atherosclerosis: the response-to-influx theory. J Vasc Res 2004 41 1 17. doi: 10.1159/000076124
300. Won D, Zhu SN, Chen M, Teichert AM, Fish JE, Matouk CC, Bonert M, Ojha M, Marsden PA, Cybulsky MI, Relative reduction of endothelial nitric-oxide synthase expression and transcription in atherosclerosis-prone regions of the mouse aorta and in an in vitro model of disturbed flow. Am J Pathol 2007 171 1691 1704. doi: 10.2353/ajpath.2007.060860
301. Hahn C, Schwartz MA, Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol 2009 10 53 62. doi: 10.1038/nrm2596
302. Pan S, Molecular mechanisms responsible for the atheroprotective effects of laminar shear stress. Antioxid Redox Signal 2009 11 1669 1682. doi: 10.1089/ars.2009.2487
303. Leopold JA, Loscalzo J, Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med 2009 47 1673 1706. doi: 10.1016/j.freeradbiomed.2009.09.009
304. Steinberg D, The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009 50 Suppl S376 S381. doi: 10.1194/jlr.R800087-JLR200
305. Steinberg D, Witztum JL, Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010 30 2311 2316. doi: 10.1161/ATVBAHA.108.179697
306. Libby P, Ridker PM, Hansson GK, Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 317 325. doi: 10.1038/nature10146
307. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stöckl J, Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010 12 1009 1059. doi: 10.1089/ars.2009.2597
308. Binder CJ, Papac-Milicevic N, Witztum JL, Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol 2016 16 485 497. doi: 10.1038/nri.2016.63
309. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD, Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999 103 1597 1604. doi: 10.1172/JCI5897
310. Cyrus T, Praticò D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD, Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001 103 2277 2282
311. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D, 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 2001 104 1646 1650
312. Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, Klein EA, Praticò D, Rader DJ, Hunter CA, Puré E, Funk CD, Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 2002 277 35350 35356. doi: 10.1074/jbc.M205738200
313. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ, Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000 275 17527 17535. doi: 10.1074/jbc.M910376199
314. Hörkkö S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, Witztum JL, Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999 103 117 128. doi: 10.1172/JCI4533
315. Binder CJ, Hörkkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ, Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003 9 736 743. doi: 10.1038/nm876
316. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, Yano J, Cercek B, Shah PK, Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006 189 83 90. doi: 10.1016/j.atherosclerosis.2005.11.033
317. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ, B cells and humoral immunity in atherosclerosis. Circ Res 2014 114 1743 1756. doi: 10.1161/CIRCRESAHA.113.301145
318. Kirabo A, Fontana V, de Faria AP, DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest 2014 124 4642 4656. doi: 10.1172/JCI74084
319. Pober JS, Is hypertension an autoimmune disease? J Clin Invest 2014 124 4234 4236. doi: 10.1172/JCI77766
320. Goss SP, Hogg N, Kalyanaraman B, The effect of nitric oxide release rates on the oxidation of human low density lipoprotein. J Biol Chem 1997 272 21647 21653
321. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S, Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993 334 170 174
322. Kumano-Kuramochi M, Shimozu Y, Wakita C, Ohnishi-Kameyama M, Shibata T, Matsunaga S, Takano-Ishikawa Y, Watanabe J, Goto M, Xie Q, Komba S, Uchida K, Machida S, Identification of 4-hydroxy-2-nonenal-histidine adducts that serve as ligands for human lectin-like oxidized LDL receptor-1. Biochem J 2012 442 171 180. doi: 10.1042/BJ20111029
323. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV, Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010 467 972 976. doi: 10.1038/nature09421
324. Mehta JL, Sanada N, Hu CP, Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007 100 1634 1642. doi: 10.1161/CIRCRESAHA.107.149724
325. Yokoyama C, Aoyama T, Ido T, Kakino A, Shiraki T, Tanaka T, Nishigaki K, Hasegawa A, Fujita Y, Sawamura T, Minatoguchi S, Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin. PLoS One 2016 11 e0154994. doi: 10.1371/journal.pone.0154994
326. Mullick AE, Soldau K, Kiosses WB, Bell TA 3rd, Tobias PS, Curtiss LK, Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 2008 205 373 383. doi: 10.1084/jem.20071096
327. Korenaga R, Ando J, Kosaki K, Isshiki M, Takada Y, Kamiya A, Negative transcriptional regulation of the VCAM-1 gene by fluid shear stress in murine endothelial cells. Am J Physiol 1997 273 C1506 C1515
328. Chappell DC, Varner SE, Nerem RM, Medford RM, Alexander RW, Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res 1998 82 532 539
329. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R, Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998 18 842 851
330. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM, Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993 92 1866 1874. doi: 10.1172/JCI116778
331. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM, Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A 1996 93 9114 9119
332. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB, Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000 20 645 651
333. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D, Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995 96 1395 1403. doi: 10.1172/JCI118175
334. Bouloumie A, Marumo T, Lafontan M, Busse R, Leptin induces oxidative stress in human endothelial cells. FASEB J 1999 13 1231 1238
335. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R, Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007 117 1718 1726. doi: 10.1172/JCI29623
336. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK, Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995 96 60 68. doi: 10.1172/JCI118074
337. Spiecker M, Peng HB, Liao JK, Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem 1997 272 30969 30974
338. Niu XF, Smith CW, Kubes P, Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res 1994 74 1133 1140
339. Kubes P, Suzuki M, Granger DN, Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991 88 4651 4655
340. Lehoux S, Redox signalling in vascular responses to shear and stretch. Cardiovasc Res 2006 71 269 279. doi: 10.1016/j.cardiores.2006.05.008
341. Chiu JJ, Wung BS, Shyy JY, Hsieh HJ, Wang DL, Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1997 17 3570 3577
342. Shuvaev VV, Han J, Tliba S, Arguiri E, Christofidou-Solomidou M, Ramirez SH, Dykstra H, Persidsky Y, Atochin DN, Huang PL, Muzykantov VR, Anti-inflammatory effect of targeted delivery of SOD to endothelium: mechanism, synergism with NO donors and protective effects in vitro and in vivo. PLoS One 2013 8 e77002. doi: 10.1371/journal.pone.0077002
343. Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA, Krieger M, Wagner DD, Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ Res 2008 103 598 605. doi: 10.1161/CIRCRESAHA.108.174870
344. Sharma A, Yuen D, Huet O, Pickering R, Stefanovic N, Bernatchez P, de Haan JB, Lack of glutathione peroxidase-1 facilitates a pro-inflammatory and activated vascular endothelium. Vascul Pharmacol 2016 79 32 42. doi: 10.1016/j.vph.2015.11.001
345. Moore KJ, Sheedy FJ, Fisher EA, Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013 13 709 721. doi: 10.1038/nri3520
346. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW, Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002 277 49982 49988. doi: 10.1074/jbc.M209649200
347. Duewell P, Kono H, Rayner KJ, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010 464 1357 1361. doi: 10.1038/nature08938
348. Tabas I, Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010 10 36 46. doi: 10.1038/nri2675
349. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007 297 842 857. doi: 10.1001/jama.297.8.842
350. Schmidt HH, Stocker R, Vollbracht C, Paulsen G, Riley D, Daiber A, Cuadrado A, Antioxidants in Translational Medicine. Antioxid Redox Signal 2015 23 1130 1143. doi: 10.1089/ars.2015.6393
351. Bast A, Haenen GR, Ten misconceptions about antioxidants. Trends Pharmacol Sci 2013 34 430 436. doi: 10.1016/j.tips.2013.05.010
352. Münzel T, Gori T, Bruno RM, Taddei S, Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010 31 2741 2748. doi: 10.1093/eurheartj/ehq396
353. Altenhöfer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH, Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. Antioxid Redox Signal 2015 23 406 427. doi: 10.1089/ars.2013.5814
354. Apostolova N, Victor VM, Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid Redox Signal 2015 22 686 729. doi: 10.1089/ars.2014.5952
355. Li H, Forstermann U, Pharmacological prevention of eNOS uncoupling. Curr Pharm Des 2014 20 3595 3606